Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26205965 | 0.89 | TSHR (0.43) | LTB4RDHFRFFAR1FFAR4MMP2 | |
| SCHEMBL26205926 | 0.85 | FFAR1 (0.42) | FFAR1FFAR4MMP2MMP12ITGB1 | |
| SCHEMBL26205966 | 0.83 | FFAR4 (0.37) | FFAR1FFAR4 | |
| SCHEMBL26205927 | 0.82 | FFAR1 (0.40) | FFAR1 | |
| SCHEMBL26238286 | 0.82 | AAK1 (0.42) | LTB4RITGB1ITGA4 | |
| SCHEMBL26205967 | 0.82 | LTB4R (0.33) | LTB4RFFAR1FFAR4MMP2MMP12 | |
| SCHEMBL26205938 | 0.81 | CYSLTR2 (0.35) | LTB4RFFAR4 | |
| SCHEMBL26205964 | 0.79 | FFAR1 (0.34) | FFAR1FFAR4MMP2MMP12ITGB1 | |
| SCHEMBL26206475 | 0.79 | S1PR2 (0.37) | LTB4RFFAR1FFAR4 | |
| SCHEMBL30341933 | 0.78 | AAK1 (0.47) | LTB4RDHFRITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | LTB4R 2439/4885DHFR 77/4885FFAR1 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.